The polypill consisted of three medications: a statin to reduce cholesterol, an ACE inhibitor to lower blood pressure, and aspirin to reduce blood clots.
The study, published in The New England Journal of Medicine, followed almost 2,500 people split into polypill users and traditional medication users.
Researchers plan to submit the study for FDA approval. It’s not the first time the FDA has met to discuss polypills; however, none have been approved yet, according to NBC News. The pill used in this study was approved in Europe in 2014.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
